Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

ProteoNic and OET Sign UNic™ License for Use in flashBAC™

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13.

ProteoNic BV and Oxford Expression Technologies Ltd (OET) have extended their partnership by signing a commercial license agreement.

OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services.

ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.

Under a previous collaboration, the two companies have successfully combined ProteoNic’s award-winning UNic™ translation enhancing technology with OET’s flashBAC™ system to significantly enhance recombinant protein yields in insect cells.

Application of UNic™ not only allows increased overall efficiency and reduction of costs, but also facilitates (pre)clinical development of biopharmaceutical products that otherwise might be discarded due to difficulties in achieving acceptable production levels.

This allows biopharmaceutical companies to broaden their pipeline and increase its value while reducing the drug development risk profile. From now on OET’s contract manufacturing services will include UNic™ technology.

Rory Woodhouse, Sales Manager at OET commented: “The combination of the unique UNic™ technology and the flashBAC™ expression system has already proved itself to have a positive effect on eukaryotic protein expression. This new agreement will enable us to build on our partnership and experience with ProteoNic, working together to provide a superior platform for our customers with more challenging to express proteins.”

Victor Schut, Chief Business Officer at ProteoNic added: “We are pleased to have demonstrated the value of partnership in combining two proven technologies. This will allow our customers to benefit from both our expertise through only one service. The successful application of our technology in the flashBAC system adds another recombinant protein production platform to our portfolio enabling us to serve a new market for ProteoNic.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProteoNic Announces Closing of Financing Round
Completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund.
Monday, October 03, 2011
ProteoNic and OET Join Forces Combining UNic™ with flashBAC™ Protein Expression Platform
Companies combine ProteoNic’s award winning UNic™ translation enhancement technology with OET’s flashBAC™ system to enhance protein yields.
Thursday, March 10, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos